A review of the GOLD guidelines for the diagnosis and treatment of patients with COPD

International Journal of Clinical Practice

Volumn 62, Issue 8, 2008, Pages 1219-1236

  Fromer, L ^a   Cooper, C B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; FORMOTEROL; INFLUENZA VACCINE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; METHYLXANTHINE; PLACEBO; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG MEGADOSE; FORCED EXPIRATORY VOLUME; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GUIDELINE; HEALTH CARE PERSONNEL; HUMAN; INFLUENZA; LUNG RESECTION; MONOTHERAPY; OXYGEN THERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; RESPIRATORY TRACT EXAMINATION; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; SPIROMETRY; SYMPTOMATOLOGY;

BRONCHODILATOR AGENTS; GUIDELINE ADHERENCE; HUMANS; OXYGEN; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPIROMETRY;

EID: 47149101943     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01807.x     Document Type: Review

References (116)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2006). http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2= 1&intId=989 (accessed August 2007).
2. Anonymous. Chartbook on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD : National Heart, Lung, and Blood Institute, 2007.
3. Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007 4 : 502 6.
4. Rutschmann OT, Janssens JP, Vermeulen B, Sarasin FP. Knowledge of guidelines for the management of COPD: a survey of primary care physicians. Respir Med 2004 98 : 932 7.
5. Rabe KF, Hurd S, Anzueto A et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD executive summary. Am J Respir Crit Care Med 2007 176 : 532 55.
6. American Thoracic Society/European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD. Version 1.2, 2004. http://www.thoracic.org/go/copd (accessed September 2007).
7. O'Donnell DE, Aaron S, Bourbeau J et al. Canadian thoracic society recommendations for management of chronic obstructive pulmonary disease. Can Resp J 2003 10 (Suppl. A 11A 65A.
8. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004 59 (Suppl. 1 1 232.
9. Tsagaraki V, Markantonis SL, Amfilochiou A. Pharmacotherapeutic management of COPD patients in Greece - adherence to international guidelines. J Clin Pharm Ther 2006 31 : 369 74.
10. Buist AS. Similarities and differences between asthma and chronic obstructive pulmonary disease: treatment and early outcomes. Eur Respir J Suppl 2003 39 : 30s 5s.
11. Buffels J, Degryse J, Heyrman J, Decramer M. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. Chest 2004 125 : 1394 9.
12. Miravitlles M, Mayordomo C, Artes M et al. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitacion Obstructiva al Flujo aEreo. Respir Med 1999 93 : 173 9.
13. Heffner JE. Using COPD guidelines to improve patient care. Am Fam Physician 2006 73 : 590 1.
14. Mularski RA, Asch SM, Shrank WH et al. The quality of obstructive lung disease care for adults in the United States as measured by adherence to recommended processes. Chest 2006 130 : 1844 50.
15. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003 22 : 672 88.
16. Pinto-Plata V, Toso J, Lee K et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007 62 : 595 601.
17. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997 156 : 341 57.
18. Ranes J, Stoller JK. A review of alpha-1 antitrypsin deficiency. Semin Respir Crit Care Med 2005 26 : 154 66.
19. Stoller JK. Alpha-1 antitrypsin deficiency: an under-recognized but important issue for respiratory therapists. Respir Care 2003 48 : 1022 4.
20. Bergeron C, Boulet LP. Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest 2006 129 : 1068 87.
21. Jeffery PK. Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004 1 : 176 83.
22. Fabbri LM, Romagnoli M, Corbetta L et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003 167 : 418 24.
23. Barnes PJ. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004 1 : 264 8.
24. Guerra S. Overlap of asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2005 11 : 7 13.
25. Elias JA. Airway remodeling in asthma. Unanswered questions. Am J Respir Crit Care Med 2000 161 : S168 71.
26. Dewar M, Curry RW Jr. Chronic obstructive pulmonary disease: diagnostic considerations. Am Fam Physician 2006 73 : 669 76.
27. Ferguson GT. Why does the lung hyperinflate? Proc Am Thorac Soc 2006 3 : 176 9.
28. Cooper CB. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 2006 119 : 21 31.
29. Tinkelman D, Corsello P. Chronic obstructive pulmonary disease: the impact occurs earlier than we think. Am J Manag Care 2003 9 : 767 71.
30. Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma 2006 43 : 75 80.
31. Tiep BL, Carter R. COPD Disease Management. http://www.thoracic.org/ sections/clinical-information/best-of-the-web/pages/obstructive-disease/ copd-disease-management.html (accessed December 2007).
32. Hughes SL, Weaver FM, Giobbie-Hurder A et al. Effectiveness of team-managed home-based primary care: a randomized multicenter trial. JAMA 2000 284 : 2877 85.
33. Bourbeau J, Collet JP, Schwartzman K et al. Economic benefits of self-management education in COPD. Chest 2006 130 : 1704 11.
34. Currie GP, Rossiter C, Miles SA et al. Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006 19 : 112 9.
35. Mahler DA. The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2002 110 : S298 303.
36. Cooper CB, Tashkin DP. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ 2005 330 : 640 4.
37. Tashkin DP. Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease? Curr Opin Pulm Med 2005 11 : 121 8.
38. Briggs DD Jr, Doherty DE. Long-term pharmacologic management of patients with chronic obstructive pulmonary disease. Clin Cornerstone 2004 Suppl 2 : S17 28.
39. van Noord JA, Smeets JJ, Custers FL et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002 19 : 639 44.
40. Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther 2005 27 : 377 92.
41. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002 19 : 217 24.
42. Vincken W, van Noord JA, Greefhorst AP et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002 19 : 209 16.
43. van Noord JA, Bantje TA, Eland ME et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000 55 : 289 94.
44. Lotvall J. Pharmacology of bronchodilators used in the treatment of COPD. Respir Med 2000 94 (Suppl. E S6 10.
45. Rodriguez-Carballeira M, Heredia JL, Rue M et al. The bronchodilator test with increasing doses of terbutaline in chronic obstructive pulmonary disease patients. Pulm Pharmacol Ther 2001 14 : 61 5.
46. Pino-Garcia JM, Garcia-Rio F, Gomez L et al. Short-term effects of inhaled beta-adrenergic agonist on breathlessness and central inspiratory drive in patients with nonreversible COPD. Chest 1996 110 : 637 41.
47. Benhamou D, Cuvelier A, Muir JF et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med 2001 95 : 817 21.
48. Bensch G, Lapidus RJ, Levine BE et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 2001 86 : 19 27.
49. Kottakis J, Cioppa GD, Creemers J et al. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J 2002 9 : 107 15.
50. Condemi JJ. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial. Clin Ther 2001 23 : 1529 41.
51. Lipson DA. Redefining treatment in COPD: new directions in bronchodilator therapy. Treat Respir Med 2004 3 : 89 95.
52. Rossi A, Kristufek P, Levine BE et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002 121 : 1058 69.
53. Dahl R, Greefhorst LA, Nowak D et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 164 : 778 84.
54. Hanania NA, Kalberg C, Yates J et al. The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm Pharmacol Ther 2005 18 : 19 22.
55. Mahler DA, Donohue JF, Barbee RA et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999 115 : 957 65.
56. ® (formoterol fumarate inhalation powder). Full Prescribing Information, Kenilworth, NJ : Schering Corporation, 2006.
57. ® (salmeterol xinafoate inhalation powder). Full Prescribing Information. Research Triangle Park, NC : GlaxoSmithKline, 2006.
58. Nelson HS, Weiss ST, Bleecker ER et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006 129 : 15 26.
59. Mann M, Chowdhury B, Sullivan E et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003 124 : 70 4.
60. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003 167 : 813 8.
61. ZuWallack RL, Mahler DA, Reilly D et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001 119 : 1661 70.
62. Cazzola M, Centanni S, Santus P et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004 98 : 1214 21.
63. Cazzola M, Di Perna F, Califano C et al. Incremental benefit of adding oxitropium bromide to formoterol in patients with stable COPD. Pulm Pharmacol Ther 1999 12 : 267 71.
64. van Noord JA, Aumann JL, Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005 26 : 214 22.
65. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994 105 : 1411 9.
66. Tashkin D, Varghese S. Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD (Abstract). J Allergy Clin Immunol 2007 119 : S4.
67. Newton MF, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002 121 : 1042 50.
68. Rabe KF, Timmer W, Sagriotis A, Viel K. [Abstract] Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. Eur Respir J 2005 26 : 14s.
69. Burge PS, Calverley PM, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000 320 : 1297 303.
70. Vestbo J, Sorensen T, Lange P et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999 353 : 1819 23.
71. Pauwels RA, Lofdahl CG, Laitinen LA et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999 340 : 1948 53.
72. Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 356 : 775 89.
73. Celli B, Ferguson G, Anderson J et al. Salmeterol/Fluticasone Propionate (SFC) Improves Lung Function and Reduces the Rate of Decline Over Three Years in the TORCH Survival Study. (Abstract). Am J Respir Crit Care Med 2007 175 : A763.
74. Hanania NA, Darken P, Horstman D et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003 124 : 834 43.
75. Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003 21 : 74 81.
76. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007 175 : 144 9.
77. Calverley PM, Boonsawat W, Cseke Z et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003 22 : 912 9.
78. Wongsurakiat P, Maranetra KN, Wasi C et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004 125 : 2011 20.
79. Lee TA, Weaver FM, Weiss KB. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. J Gen Intern Med 2007 22 : 62 7.
80. Alfageme I, Vazquez R, Reyes N et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006 61 : 189 95.
81. Celli BR. Pulmonary rehabilitation in patients with COPD. Am J Respir Crit Care Med 1995 152 : 861 4.
82. Clark NM, Nothwehr F, Gong M et al. Physician-patient partnership in managing chronic illness. Acad Med 1995 70 : 957 9.
83. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977 1 : 1645 8.
84. Fiore MC, Bailey WC, Cohen SJ et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD : U.S. Department of Health and Human Services. Public Health Service, June 2000.
85. Celli BR. Pulmonary rehabilitation for COPD. A practical approach for improving ventilatory conditioning. Postgrad Med 1998 103 : 159 60, 67 8, 73 6.
86. Cooper CB. Exercise in chronic pulmonary disease: aerobic exercise prescription. Med Sci Sports Exerc 2001 33 : S671 9.
87. Storer TW. Exercise in chronic pulmonary disease: resistance exercise prescription. Med Sci Sports Exerc 2001 33 : S680 92.
88. Green RH, Singh SJ, Williams J, Morgan MD. A randomised controlled trial of four weeks versus seven weeks of pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax 2001 56 : 143 5.
89. Casaburi R, Porszasz J, Burns MR et al. Physiologic benefits of exercise training in rehabilitation of patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997 155 : 1541 51.
90. Porszasz J, Emtner M, Goto S et al. Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD. Chest 2005 128 : 2025 34.
91. Casaburi R, Kukafka D, Cooper CB et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005 127 : 809 17.
92. Chailleux E, Laaban JP, Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory. Chest 2003 123 : 1460 6.
93. Sahebjami H, Sathianpitayakul E. Influence of body weight on the severity of dyspnea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000 161 : 886 90.
94. California Pulmonary Rehabilitation Collaborative Group. Effects of pulmonary rehabilitation on dyspnea, quality of life, and healthcare costs in California. J Cardiopulm Rehabil 2004 24 : 52 62.
95. Ries AL, Kaplan RM, Myers R, Prewitt LM. Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. Am J Respir Crit Care Med 2003 167 : 880 8.
96. Tarpy SP, Celli BR. Long-term oxygen therapy. N Engl J Med 1995 333 : 710 4.
97. Petty TL, Bliss PL. Ambulatory oxygen therapy, exercise, and survival with advanced chronic obstructive pulmonary disease (the Nocturnal Oxygen Therapy Trial revisited). Respir Care 2000 45 : 204 11 discussion 11-3.
98. Budweiser S, Hitzl AP, Jorres RA et al. Impact of noninvasive home ventilation on long-term survival in chronic hypercapnic COPD: a prospective observational study. Int J Clin Pract 2007 61 : 1516 22.
99. Kolodziej MA, Jensen L, Rowe B, Sin D. Systematic review of noninvasive positive pressure ventilation in severe stable COPD. Eur Respir J 2007 30 : 293 306.
100. Kramer N, Meyer TJ, Meharg J et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 1995 151 : 1799 806.
101. Brochard L, Isabey D, Piquet J et al. Reversal of acute exacerbations of chronic obstructive lung disease by inspiratory assistance with a face mask. N Engl J Med 1990 323 : 1523 30.
102. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 2000 355 : 1931 5.
103. Mehran RJ, Deslauriers J. Indications for surgery and patient work-up for bullectomy. Chest Surg Clin N Am 1995 5 : 717 34.
104. Martinez FJ, de Oca MM, Whyte RI et al. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 1997 155 : 1984 90.
105. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001 345 : 1075 83.
106. Patel N, Criner GJ. Transplantation in chronic obstructive pulmonary disease. COPD 2006 3 : 149 62.
107. Stavem K, Bjortuft O, Borgan O et al. Lung transplantation in patients with chronic obstructive pulmonary disease in a national cohort is without obvious survival benefit. J Heart Lung Transplant 2006 25 : 75 84.
108. Wang Q, Bourbeau J. Outcomes and health-related quality of life following hospitalization for an acute exacerbation of COPD. Respirology 2005 10 : 334 40.
109. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005 60 : 925 31.
110. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax 2006 61 : 250 8.
111. Hernandez C, Casas A, Escarrabill J et al. Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients. Eur Respir J 2003 21 : 58 67.
112. Anthonisen NR, Manfreda J, Warren CP et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987 106 : 196 204.
113. Aaron SD, Vandemheen KL, Hebert P et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003 348 : 2618 25.
114. Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ 2003 327 : 643.
115. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999 354 : 456 60.
116. Ram FS, Rodriguez-Roisin R, Granados-Navarette A et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease (Review). Cochrane Database Syst Rev 2007 3 : 1 39.